Diplomatic Trade Ltd has finalized a significant cross-border investment in the Turkish pharmaceutical sector, acquiring a controlling 49% equity position in Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S. The transaction represents a major strategic move to expand pharmaceutical manufacturing capabilities in the Middle East and North Africa (MENA) region.
The investment includes plans to launch a next-generation bio-manufacturing facility in the UAE by the third quarter of 2025. This facility will specialize in biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals, targeting growing healthcare demands across Gulf states and North Africa.
With advanced technological integration, the new facility will feature AI-driven quality control, biocompatible packaging, and production suites that meet European Union Good Manufacturing Practice (EU-GMP) standards. The venture aims to enhance pharmaceutical supply chain independence and innovation in the region.
The partnership has significant financial backing from Morgan Brookshire LLC, a U.S.-based private family office. The companies are targeting an initial public offering (IPO) on a leading UAE stock exchange in the fourth quarter of 2025, with early projections estimating a valuation near $300 million.
This strategic investment underscores a broader trend of transatlantic collaboration in life sciences, bridging healthcare innovation between the United States and Gulf Cooperation Council (GCC) markets. The deal positions Diplomatic Trade Ltd as a key player in regional pharmaceutical consolidation and emerging market healthcare infrastructure development.
